These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Algvere PV; Steén B; Seregard S; Kvanta A Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062 [TBL] [Abstract][Full Text] [Related]
8. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization. Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461 [TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients. Pedersen KB; Sjølie AK; Møller F Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171 [TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Chan WM; Lai TY; Liu DT; Lam DS Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414 [TBL] [Abstract][Full Text] [Related]
11. The treatment of choroidal neovascularizations in age-related macular degeneration using either Avastin or Lucentis. Valmaggia C; Haueter I; Kloos P; Lang C; Niederberger H Klin Monbl Augenheilkd; 2009 Apr; 226(4):294-8. PubMed ID: 19384786 [TBL] [Abstract][Full Text] [Related]
12. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G Retina; 2006; 26(5):495-511. PubMed ID: 16770255 [TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab for choroidal neovascularisation associated with pseudoxanthoma elasticum. Finger RP; Charbel Issa P; Ladewig M; Holz FG; Scholl HP Br J Ophthalmol; 2008 Apr; 92(4):483-7. PubMed ID: 18369065 [TBL] [Abstract][Full Text] [Related]
14. Bevacizumab for choroidal neovascularization related to inflammatory diseases. Kramer M; Axer-Siegel R; Jaouni T; Reich E; Hemo I; Priel E; Averbukh E; Ehrlich R; Chowers I; Weinberger D; Amer R Retina; 2010 Jun; 30(6):938-44. PubMed ID: 20168273 [TBL] [Abstract][Full Text] [Related]
15. Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization. Inoue M; Kadonosono K; Watanabe Y; Sato S; Kobayashi S; Yamane S; Ito R; Arakawa A Retina; 2010 May; 30(5):733-8. PubMed ID: 20168271 [TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab for subfoveal choroidal neovascularization associated with pattern dystrophy. Parodi MB; Iacono P; Cascavilla M; Zucchiatti I; Kontadakis DS; Bandello F Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4358-61. PubMed ID: 20375343 [TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Chan WM; Lai TY; Liu DT; Lam DS Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318 [TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Costa RA; Jorge R; Calucci D; Cardillo JA; Melo LA; Scott IU Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4569-78. PubMed ID: 17003454 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]